Factors that influence the bleeding phenotype in severe hemophilic patients

被引:18
作者
Rendo, Pablo [1 ]
Shafer, Frank [1 ]
Korth-Bradley, Joan M. [1 ]
Sivamurthy, Krupa [1 ]
Korin, Jorge [2 ]
机构
[1] Pfizer Inc, Collegeville, PA 19426 USA
[2] Consultorios Hematol, Buenos Aires, DF, Argentina
关键词
blood coagulation disorder; hemophilia A; hemophilia B; inherited; ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; RHEUMATOID-ARTHRITIS; CLINICAL SEVERITY; FACTOR-VIII; PROPHYLACTIC TREATMENT; PROMOTER POLYMORPHISM; VENOUS THROMBOSIS; DISEASE-ACTIVITY;
D O I
10.1097/MBC.0b013e3283614210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemophilia A and B are rare, X-linked bleeding disorders resulting from a partial or total deficiency of functionally active coagulation factor VIII or factor IX, respectively. Endogenous factor levels have traditionally been used to characterize the severity of the disorder, with severe hemophilia considered as circulating levels of factor less than 1% of normal. Identifying patients with severe hemophilia is essential to effective treatment, since these patients are at highest risk of spontaneous life or limb-threatening bleeding and disability resulting from repeated joint bleeding and are most likely to benefit from prophylaxis. However, there is variability in bleeding tendency, even among patients with severe hemophilia. This article will review potential modifiers of hemophilia-associated bleeding other than endogenous factor activity, which may influence bleeding tendencies and complications in hemophilic patients considered to have severe hemophilia. These potential modifiers include physiologic factors, such as elements of the hemostatic system; pathophysiologic factors, such as hemophilic arthropathy, associated inflammation, and angiogenesis; and others, such as seasonal variation, body weight, and physical activity. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 72 条
[1]   Neoangiogenesis contributes to the development of hemophilic synovitis [J].
Acharya, Suchitra S. l ;
Kaplan, Rosandra N. ;
Macdonald, Dan ;
Fabiyi, Oluwa T. ;
DiMichele, Donna ;
Lyden, David .
BLOOD, 2011, 117 (08) :2484-2493
[2]   Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A? [J].
Ahmed, R ;
Kannan, M ;
Choudhry, VP ;
Saxena, R .
THROMBOSIS RESEARCH, 2003, 109 (01) :71-72
[3]   A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia [J].
Ahnström, J ;
Berntorp, E ;
Lindvall, K ;
Björkman, S .
HAEMOPHILIA, 2004, 10 (06) :689-697
[4]  
[Anonymous], 2009, BLEED DIS FAQS
[5]  
[Anonymous], 2012, PROTHR G20210A MUT B
[6]  
[Anonymous], 2011, REP ANN GLOB SURV 20
[7]  
Bauer KA, 2008, HEMATOLOGY BASIC PRI, P2021
[8]   PERIODIC HAEMORRHAGES IN HAEMOPHILIA A [J].
BENBASSA.J .
BRITISH MEDICAL JOURNAL, 1971, 3 (5777) :771-&
[9]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[10]   Haemophilias A and B [J].
Bolton-Maggs, PHB ;
Pasi, KJ .
LANCET, 2003, 361 (9371) :1801-1809